Biocept Ceo






SAN DIEGO, June 25, 2018 /PRNewswire/ -- Biocept, Inc. He is the Chairman & CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Biocept, Inc. The best long-term & short-term Biocept, Inc. SAN DIEGO, Aug. CEO Mike Nall said the company will provide the critical testing to physicians to fight the global coronavirus pandemic. Biocept (BIOC) Recent Earnings. We partner with industry leaders and major cancer centers, continually advancing the field of. Growing? Biocept, Inc. Janko was also the President/CEO of Biocept, Inc. Biocept - Proactive's One2One Virtual Investor Forum. At the time of writing, our data says that Biocept, Inc. A free inside look at Biocept offices and culture posted anonymously by employees. Biocept President and CEO Michael Hall said in a statement that McNeal's experience will be essential as the company works to expand coverage for its OncoCEE-BR breast cancer liquid biopsy test,. 13 in a total of its share price and finished its trading at 0. SAN DIEGO, May 29, 2020 /PRNewswire/ — Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of. The biotechnology company said it has provided the regulator with a top-line report from its recently. Biocept Inc.  “Mike is particularly known within our industry for his outstanding leadership capability and commercial vision. com Morningstar 24 mins Wild up and down day for US equities. CytoDyn Inc (OTCQB:CYDY) said it has requested the regulatory pathway for Fast Track approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its leronlimab treatment to provide it to coronavirus patients. (NASDAQ:BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable. Janko was also the President/CEO of Biocept, Inc. com - SAN DIEGO, May 20, 2020 /PRNewswire/ - Biocept, Inc. Biocept wiki. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall presents to investors at Proactive's One2One Virtual Investor Forum. , San Diego, Calif. Togo Group CEO on road trip trends. Biocept shares were jumping 63. Biocept to begin coronavirus testing Local. Dr Dugan brings to Biocept more than 25 years of industry experience, most recently as president and CEO of MCDXI Medical Diagnostics International, a professional advisory group practice where he consulted with biotechnology companies in oncology diagnostics, medical device development, and clinically related software applications. "We began by providing COVID-19 testing services to a few facilities within this group, and they have been impressed by our quick turnaround times, with the vast majority of our COVID-19 testing results reported within 48 hours," said Michael Nall, President and CEO of Biocept. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Athersys was moving up 8. Biocept, Inc Stock Price Forecast, "BIOC" Predictons for2020. This is hosted by Maxim Group and M-Vest being held on Wednesday, May 27. Biocept (NASDAQ:BIOC) CEO Mike Nall will be presenting at Proactive's One2One Virtual Event on Tuesday, August 25th at 1pm EST. (NASDAQ:BIOC) in 2013. /PRNewswire/ -- Biocept, Inc. Biocept, Inc. SAN DIEGO, May 29, 2020 /PRNewswire/ — Biocept, Inc. 4 million, representing a 41% increase over the prior-year period driven by a 27% increase in revenue per commercial accession,' said Michael Nall, President and CEO of Biocept. Read More Ballville Dam. BIOC Stock Message Board: I don't know about the CEO, but constant. Biocept is one of Biotheranostics's top rivals. The declines come after the company issued its financial results, leaving investors with mixed feelings. Dugan brings to Biocept more than 25 years of industry experience, most recently as President and CEO of MCDXI Medical Diagnostics International, a professional advisory group practice where he consulted with biotechnology companies in oncology diagnostics, medical device development, and clinically related software applications. SAN DIEGO, Aug. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, and Aegea Biotechnologies, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. BIO CEO & Investor Conference Feb 10-11, 2020 New York, New York. (CSE:VS) (OTCQB:VRSSF) (FSE:BMVA), at the request of Investment Industry Regulatory Organization of Canada (IIROC), said Friday that it wished to confirm that the company's management is unaware of any material change in the company's operations that would account for the recent increase in market activity, other than the. Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility. , an innovative private life science company with an extensive portfolio of issued patents in next-generation nucleic. Dear CEO of BIOC. Biocept's top competitors are Cynvenio, Circulogene and True Health. Our Research. 20, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. Biotheranostics. 38 per share in the second quarter of 2019. 2 million funding which positions the company […]. Nall will present a corporate overview at the 22 nd Annual BIO CEO & Investor Conference on Monday. Dear CEO of BIOC. Biocept to Present at the 22nd Annual BIO CEO & Investor Conference News provided by. Nall says the. Biocept has 32 fewer employees vs. Several other executives at GE are also recently-appointed. Biocept, Inc. Kevin McCabe - LHA, IR. Since September of 2018, GE has been led by H. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at the LD Micro 500 Virtual Conference on Wednesday, September 2, at 10:40 a. Biocept will hold a conference call today at 4:30 pm Eastern time to discuss these results and answer questions. Dugan has more than 25 years of industry experience, most recently as president and CEO of professional advisory group practice MCDXI Medical Diagnostics International. Biocept, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Dugan brings to Biocept more than 25 years of industry experience, most recently as President and CEO of MCDXI Medical Diagnostics International, a professional advisory group practice where. "We have. com Morningstar 30 mins Wild up and down day for US equities. The company offers OncoCEE-BR (TM) test for breast cancer. s (NASDAQ:BIOC) CEO Salary Level? Simply Wall St. 24, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. Trending now. Dr Dugan brings to Biocept more than 25 years of industry experience, most recently as president and CEO of MCDXI Medical Diagnostics International, a professional advisory group practice where he consulted with biotechnology companies in oncology diagnostics, medical device development, and clinically related software applications. 28, 2020, reporting to CEO Francis deSouza. BIOCEPT INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. 14, 2020 -- (Healthcare Sales & Marketing Network) -- Biocept, Inc. Biocept to begin coronavirus testing in its highly advanced and certified lab in San Diego. That valuation puts Biocept’s market value at $48 million, according to a summary of the initial public offering by Renaissance. 0% compared to the same quarter a year ago. (Nasdaq: BIOC), a leading commercial provider. Hale was appointed Executive Chairman of Biocept in March 2011. 85% Biocept, Inc. Tim Kennedy - SVP, Operations. SAN DIEGO, Aug. 78%, while year-to-date (YTD) performance is 85. Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility. Stock Price Forecast, BIOC stock price prediction. The group is a commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. "But after six or seven years with no commercial success," Reiss brought in a new CEO who refocused the company on microfluidics, according to Coutts. 7729 Company Operator: 858. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. NEW YORK -- Biocept - Get Report shares are rallying 6. SAN DIEGO, Aug. The Board of Directors of Biocept Inc. Diagnostics Oncology Personnel News Release - February 14, 2020 Biocept Appoints Cory J. (NASDAQ: BIOC) via Skype. BIO CEO & Investor Conference Feb 10-11, 2020 New York, New York. Biocept wiki. Rumor Buzz of GE Healthcare buyout of Biocept Inc. 16M Navy contract - Bell Textron was awarded a $272. He is the Chairman & CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Culp is the 12th CEO in the company's history. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients. patent to detect rare mutations and cancer biomarkers 18 Aug 2020 - Seeking Alpha - Article Biocept to provide COVID-19 testing to multi-state locations 13 Aug 2020 - Seeking. 64% over the past 2 weeks. Athersys was moving up 8. He also brings to Biocept diverse HR experience, including Manager of Organization Learning and Development at Starwood Hotel and Resorts, HR Manager with The Walt Disney Company, Director of Technical Services at Perimeter Church, and CEO of Gamy and Ary, Inc. "We are grateful to call San Diego our home and to find a well-suited location that is convenient for our employees," said Michael Nall, President and CEO of Biocept. Biocept, Inc. 435 until finishing in the latest session at $0. 4, 2020 /PRNewswire/ -- Biocept, Inc. In a statement, Michael Nall, CEO at BIOC, had the following to offer: This project further expands on Biocept’s initiatives in the COVID-19 PCR testing market and highlights our capabilities to develop high-complexity molecular-based assays based on our core Switch-Blocker technology for multiple applications, including potentially COVID-19. Biocept (BIOC) Presents At BIO CEO & Investor Conference 2020 - Slideshow. , an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. CA #bioc Biocept, Inc. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. Biocept, Inc. Encuentra el debate de accionesBiocept, Inc. Deprecated: implode(): Passing glue string after array is deprecated. Address: 5810 Nancy Ridge Drive, Suite 150, San Diego, CA, USA, 92121: Telephone: +1 858 320-8200: Website: https://www. The MarketWatch News Department was not involved in the creation of this content. This analysis aims first to contrast CEO compensation Simply Wall St. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. 27, 2020 SAN DIEGO, Aug. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE Mark geographies. (BIOC) como el resumen financiero, información sobre la industria y el sector, la cantidad de empleados, la gestión corporativa, los miembros ejecutivos clave y sus compensaciones. Biocept, Inc. BIOCEPT INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. 85% Biocept, Inc. Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. 27, 2020 /PRNewswire/ -- Biocept, Inc. Dugan brings to Biocept more than 25 years of industry experience, most recently as President and CEO of MCDXI Medical Diagnostics International, a professional advisory group practice where. Shares of Biocept Inc (NASDAQ: biomarker assay or a larger NGS-based liquid biopsy test panel for use when more comprehensive testing is desired," CEO Michael Nall said in a statement. 04 per share. The MarketWatch News Department was not involved in the creation of this content.  “Mike is particularly known within our industry for his outstanding leadership capability and commercial vision. The single most important factor in a company's success is the team that's leading the company. Biocept Inc. Biocept, Inc. 27, 2020 /PRNewswire/ -- Biocept, Inc. "Our ability to expand internationally is a testament to the scalability of our platform as we deliver liquid biopsy testing to the medical community worldwide," Biocept President and CEO Michael Nall said in a statement. Biocept - Proactive's One2One Virtual Investor Forum. 11, 2020 12:11 PM ET. The BIO CEO and Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. , Suite 150 San Diego, CA 92121 Customer Service: 888. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, and Aegea Biotechnologies, Inc. BIOC sais that it has partnered with a national clinician network to accept patient samples. share price prognosis for 2020, 2021, 2022, 2023, 2024. , local time, at the offices of Biocept, Inc. CytoDyn Inc (OTCQB:CYDY) said it has requested the regulatory pathway for Fast Track approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its leronlimab treatment to provide it to coronavirus patients. Togo Group CEO on road trip trends. , a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. Company Participants. 6, 2020 /PRNewswire/ -- Biocept, Inc. 05-20 prnewswire. Senior Vice President Corporate Development at Biocept, Inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE Delaware GENERAL CORPORATION LAW The undersigned, Michael W. In a statement, Michael Nall, CEO at BIOC, had the following to offer: This project further expands on Biocept’s initiatives in the COVID-19 PCR testing market and highlights our capabilities to develop high-complexity molecular-based assays based on our core Switch-Blocker technology for multiple applications, including potentially COVID-19. SAN DIEGO, Aug. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. Biocept, Inc. Biocept Inc is an early commercial-stage molecular oncology diagnostics company. This analysis aims first to contrast CEO compensation Simply Wall St. ’s ISS Governance QualityScore as of N/A is N/A. if Biocept has not regained compliance with the closing bid price requirement by. ’s ISS governance QualityScore as of N/A is N/A. Dear CEO of BIOC. 89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Diagnostics specialist Biocept. Biocept President and CEO Michael Hall said in a statement that McNeal's experience will be essential as the company works to expand coverage for its OncoCEE-BR breast cancer liquid biopsy test,. The target price ranges between 1 and 1 and has a mean target at 1. | Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated DNA , both in Circulating Tumor Cells (CTCs) and in plasma (cell free circulating tumor DNA). Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE. SAN DIEGO, Aug. Earnings for Biocept are expected to decrease in the coming year, from ($0. "They have also been pleased with our attentive customer service, test quality and on-line reporting capabilities. "This agreement provides Biocept with new incremental revenue for R&D development services and, if successfully developed. Biocept up 5% as COVID-19 test volume ramps Aug 31 / Seeking Alpha - Paid Partner Content Biocept, Inc. Dugan brings to Biocept more than 25 years of industry experience, most recently as President and CEO of MCDXI Medical Diagnostics International, a professional advisory group practice where he consulted with biotechnology companies in oncology diagnostics, medical device development, and clinically related software applications. The single most important factor in a company's success is the team that's leading the company. Biocept - Proactive's One2One Virtual Investor Forum. 85% Biocept, Inc. Biocept CEO and President Michael Nall says the company’s Target SelectorTM assays utilize a blood sample to provide biomarker analysis to physicians when tissue biopsies are inadequate or the risk to the patient is too high to attempt a surgical procedure. com - 16 - Shares of Biocept Inc. The conference call can be accessed by dialing (855) 656-0927 for domestic callers. (NASDAQ:BIOC) Q2 2019 Earnings Conference Call. In a statement, Michael W. has a market cap of US$17m, and reported total annual CEO compensation of US$440k for the year to December 2018. "This project further expands on Biocept's initiatives in the COVID-19 PCR testing market and highlights our capabilities to develop high-complexity molecular-based assays based on our core Switch-Blocker technology for multiple applications, including potentially COVID-19," said Michael Nall, President and CEO of Biocept. Biocept to Present at the LD Micro 500 Virtual Conference PR Newswire SAN DIEGO, Aug. | Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated DNA , both in Circulating Tumor Cells (CTCs) and in plasma (cell free circulating tumor DNA). Run by investors for investors Proactive Investors is a Leading source of in-depth comment, analysis, financial news, press releases and share price data on small to large capitalised companies on the Australian Stock Exchange, Toronto Stock Exchange. 7729 Company Operator: 858. , and a member of its board of directors. He is the Chairman & CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Profitability Ratios (ROE, ROA, ROI):. (BIOC) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their compensation. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, and Aegea Biotechnologies, Inc. Dugan has more than 25 years of industry experience, most recently as president and CEO of professional advisory group practice MCDXI Medical Diagnostics. 78%, while year-to-date (YTD) performance is 85. Biocept, Inc. is a commercial stage oncology diagnostics company. (Nasdaq: BIOC), a Biocept's President and CEO. Biocept to begin coronavirus testing Local. Eastern time to discuss these results and answer questions. Nall is the President and Chief Executive Officer of Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients. It comes after the group's one-for-ten (ten shares combined and converted into one) reverse stock split which became effective at 5pm EST on September 4 this year. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Michael Nall, Biocept's President and CEO. At the time of writing, our data says that Biocept, Inc. Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated DNA , both in Circulating Tumor Cells (CTCs) and in plasma (cell free circulating tumor DNA). See Michael W Nall's compensation, career history, education, & memberships. In fact, the company said that it plans to begin accepting oders from physicians and processing these orders starting on April 15, 2020. Biocept (BIOC) reported a 2nd Quarter June 2020 loss of $0. BIOC Stock Message Board: I don't know about the CEO, but constant. 8200 Fax: 858. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Michael Nall, Biocept's President and CEO, added, "We are very proud to be working with VWR, for the distribution of our proprietary liquid biopsy collection tubes. Biocept Inc (NASDAQ:BIOC) released second quarter results after the bell Wednesday that showed a narrowing loss and increase in commercial test volumes, despite the impact of the coronavirus. 14, 2020 /PRNewswire/ -- Biocept, Inc. has a market cap of US$18m, and reported total annual CEO compensation of US$440k for the year to December 2018. Dunn Senior Vice President of Commercial Operations SAN DIEGO, Feb. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. a boutique construction firm. Michael Nall - President & CEO. 27, 2020 /PRNewswire/ -- Biocept, Inc. , a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. SAN DIEGO, Aug. announces that President and CEO Michael Nall will present at the LD Micro 500. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Michael Nall, Biocept's President and CEO. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients. Biocept, Inc. Biocept’s net loss attributable to common shareholders for the second quarter of 2020 stood at $6. Feb 4, 2020 8:05AM EST. Dugan brings to Biocept more than 25 years of industry experience, most recently as President and CEO of MCDXI Medical Diagnostics International, a professional advisory group practice where he consulted with biotechnology companies in oncology diagnostics, medical device development, and clinically related software applications. The MarketWatch News Department was not involved in the creation of this content. Nall is the President and Chief Executive Officer of Biocept, Inc. Hale was appointed Executive Chairman of Biocept in March 2011. 4, 2020 /PRNewswire/ -- Biocept, Inc. , headquartered in San Diego, Calif. SAN DIEGO, June 25, 2018 /PRNewswire/ -- Biocept, Inc. Dugan has more than 25 years of industry experience, most recently as president and CEO of professional advisory group practice MCDXI Medical Diagnostics. BioCryst shares were gaining 21. The Biotechnology Innovation Organization is the world's largest biotech trade association. Biocept To Accept COVID-19 Testing Requests. Biocept (BIOC +4. "This agreement effectively expands our managed care network of covered lives at a time when the healthcare community increasingly recognizes the importance of our liquid biopsy tests in helping physicians to determine the optimal treatment for their patients with cancer," said Michael Nall, Biocept's President and CEO. ’s ISS Governance QualityScore as of N/A is N/A. Biocept, Inc. The analyst consensus points to a rating of ‘Buy’. Biocept, Inc Stock Price Forecast, "BIOC" Predictons for2020. Biocept stock (BIOC) was skyrocketing on Friday as the company announced a liquid biopsy testing partnership with Alliance Global FZ. Nall’s extensive commercialization, sales and marketing. As healthy and diseased tissue interact with the bloodstream, they release both cellular and genetic material into the circulation. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall presents to investors at Proactive's One2One Virtual Investor Forum. has inked a $15 million stock purchase agreement with Chicago-based Aspire Capital Fund LLC. is a biopharmaceutical company based in San Francisco, CA developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders. The firm has its footing in the healthcare sector, specifically in the diagnostics and research industry and employs about 95 people on a full-time basis. (NASDAQ:BIOC) since 2013. (BIOC) CEO Michael Nall on Q1 2020 Results - Earnings Call Transcript. In fact, the company said that it plans to begin accepting oders from physicians and processing these orders starting on April 15, 2020. Implicit in this philosophy is the importance of sound corporate governance. CytoDyn Inc (OTCQB:CYDY) said it has requested the regulatory pathway for Fast Track approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its leronlimab treatment to provide it to coronavirus patients. , an innovative private life science company with an extensive portfolio of issued patents in next-generation nucleic. Diagnostics specialist Biocept. Biocept wiki. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Michael Nall, Biocept's President and CEO.  “Mike is particularly known within our industry for his outstanding leadership capability and commercial vision. Dugan has more than 25 years of industry experience, most recently as president and CEO of professional advisory group practice MCDXI Medical Diagnostics. Biocept shares were jumping 63. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. 63 with the day’s price range being $0. Nall says the. 27, 2020 SAN DIEGO, Aug. Biocept, Inc. Janko was also the President/CEO of Biocept, Inc. , local time, at the offices of Biocept, Inc. 27, 2020 /PRNewswire/ -- Biocept, Inc. SAN DIEGO, Aug. Corporate Governance Biocept, Inc. the Market. SAN DIEGO, Feb. Evan discusses the latest $3. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Nall as President and Chief Executive Officer. 5810 Nancy Ridge Dr. 5%) is up, albeit on below-average volume, in reaction to its announcement that it has processed more than 20K COVID-19 specimens in its molecular lab, most reported within 48. (Nasdaq: BIOC), a leading commercial provider. Biocept's blood- based tests are also used by physicians to monitor patients' treatment in a non-invasive manner. SAN DIEGO, June 25, 2018 /PRNewswire/ -- Biocept, Inc. The company has a market cap of $71. On 05-06-2020 (Friday), BIOC stock construct a change of -11. Biocept, Inc. Entering into the global market with a scaled offering for liquid biopsy is the first step toward growing from an exclusive CLIA lab business to a technology and products company. Nall is the President and Chief Executive Officer of Biocept, Inc. Wednesday, 19 August 2020 (54 minutes ago)Biocept Inc (NASDAQ:BIOC) announced Wednesday it is expanding the availability of its coronavirus (COVID-19) testing services. SAN DIEGO, May 29, 2020 /PRNewswire/ — Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Dugan has more than 25 years of industry experience, most recently as president and CEO of professional advisory group practice MCDXI Medical Diagnostics. The analyst consensus points to a rating of ‘Buy’. Tim Kennedy - SVP, Operations. Compare pay for popular roles and read about the team’s work-life balance. Several other executives at GE are also recently-appointed. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W. Kevin McCabe - LHA, IR. Razer CEO on how the gamer giant plans to spend its $500m cash amid record results Razer CEO Min-Liang Tan speaks exclusively to Yahoo Finance UK Biocept, Inc. 27, 2020 Biocept (BIOC), Inc. Like Biotheranostics, Biocept also works within the Biotechnology industry. Janko was also the President/CEO of Biocept, Inc. Biocept, Inc Stock Price Forecast, "BIOC" Predictons for2020. (Nasdaq: BIOC), a leading commercial provider. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients. This analysis aims first to contrast CEO compensation Simply Wall St. Athersys was moving up 8. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. Learn about BIO, register for events and explore member services. 13, 2020 /PRNewswire/ -- Biocept, Inc. Biocept (BIOC) said Monday Michael Dugan has been appointed as the new chief medical officer and medical director of the cancer diagnostics company. The consensus estimate was a loss of $0. Biocept, Inc. The graphic below shows how CEO compensation at Biocept has changed from year to year. Biocept, Inc. President & CEO Ligand Dx (LW Ligand, Inc. August 12, 2019 16:30 ET. The company offers OncoCEE-BR (TM) test for breast cancer. A corporate filing is called a foreign filing when an existing corporate entity files in a. (Nasdaq: President and CEO of Biocept. Find the latest Biocept, Inc. 27% to trade at $2. Biocept shares were jumping 63. Eastern time to discuss these results and answer questions. Dugan brings to Biocept more than 25 years of industry experience, most recently as President and CEO of MCDXI Medical Diagnostics International, a professional advisory group practice where he consulted with biotechnology companies in oncology diagnostics, medical device development, and clinically related software applications. 16M fixed-price-incentive-firm-target contract for the production and delivery of eight UH-1Y and four AH-1Z helicopters for the government of the Czech Republic. Major indices close lower for the 2nd consecutive day Forexlive 35 mins S&P Snaps 5-Week Win as Tech Bulls Go Awol Investing. It is worth noting that the CEO compensation consists almost entirely of the salary, worth US$426k. "As previously reported, securing specimen collection kits to conduct RT-PCR COVID-19 testing has been challenging both for Biocept and other providers. Get Biocept Inc (B002-FF:Frankfurt Stock Exchange) real-time stock quotes, news and financial information from CNBC. (BIOC) website. Salaries, reviews and more - all posted by employees working at Biocept. A free inside look at Biocept offices and culture posted anonymously by employees. Below is a representative list of partnering companies for the 2020 CEO & Investor Conference: 20/20 GeneSystems 3E Bioventures 3i Fund A C Binder Corp A2A Pharmaceuticals Ab Studio AbbVie Abingworth Management Accelmed Partners Aceras Partners …. In fact, the company said that it plans to begin accepting oders from physicians and processing these orders starting on April 15, 2020. Kevin McCabe - LHA, IR. Miele French Door Refrigerators; Bottom Freezer Refrigerators; Integrated Columns – Refrigerator and Freezers; Interesting Features Shared Around All Designs; Is Miele Refrigerator Worth It? High-End Refrigerators with Offers at Different Price Points; Better Kitchen Integration to get a Seamless. Our liquid biopsies have been used by doctors in thousands of patient cases. Prior to joining Biocept, Michael served as General Manager for Clarient, a GE Healthcare Company, responsible for all commercial operations including Sales, Marketing, Client Services and Reimbursement. BIOCEPT INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. SAN DIEGO, Aug. The biotechnology company said it has provided the regulator with a top-line report from its recently. Togo Group CEO on road trip trends. Biocept CEO Michael Nall Now the company has its eye on expansion, planning to roll out similar tests for colorectal cancer and melanomas in the year to come, CEO Michael Nall told FierceDiagnostics. Dear CEO of BIOC. Dunn Senior Vice President of Commercial Operations SAN DIEGO, Feb. The company’s cancer assays provide an information to oncologists and other physicians that enable them to select personalized treatment for their patients based on detailed data on the characteristics of tumors. Biocept Inc. BIOC sais that it has partnered with a national clinician network to accept patient samples. Biocept, Inc. This analysis aims first to contrast CEO compensation Simply Wall St. Biocept understands that many of our clients have taken precautionary measures to help prevent the spread of the virus and some maybe delaying or rescheduling patient appointments. 27, 2020 /PRNewswire/ -- Biocept, Inc. Biocept to Present at the 22nd Annual BIO CEO & Investor Conference Published. Biocept is a Public company that was founded in San Diego, California in 1997. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE on 5/5/20. CEO is Michael W. Company Participants. "This project further expands on Biocept's initiatives in the COVID-19 PCR testing market and highlights our capabilities to develop high-complexity molecular-based assays based on our core. Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at the LD Micro 500 Virtual Conference on Wednesday, September 2, at 10:40 a. 16M Navy contract - Bell Textron was awarded a $272. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall presents to investors at Proactive's One2One Virtual Investor Forum. we just heared that bioc has until Dec 7 2020 to satisfy the Nasdaq $1 minimum bid requirement.  “Mike is particularly known within our industry for his outstanding leadership capability and commercial vision. (BIOC) CEO Michael Nall on Q2 2020 Results - Earnings Call Transcript. Reeves brings more than 25 years of marketing and management experience and comes to Illumina from Cardinal Health, where she was senior VP of enterprise marketing and general manager of the medical. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving. (BIOC Stock Report) announced that Michael W. Diagnostics specialist Biocept. 6, 2020 /PRNewswire/ --Biocept, Inc. In a statement, Michael Nall, President and CEO at BIOC, had the following to offer: Our Primer-Switch methodology has the potential to find rare mutations in PCR reactions, especially where the detection of rare genetic events is needed, or in cases where more precise PCR amplification reactions are desired or required. It's all about the AND. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. We partner with industry leaders and major cancer centers, continually advancing the field of. Biocept (BIOC +4. Biocept, Inc. Togo Group CEO on road trip trends. The company offers OncoCEE-BR (TM) test for breast cancer. June 19, 2020 – NEXT SUPER STOCK presenter, NexTech AR Solutions (OTC: NEXCF) (CSE: NTAR) Interview with CEO Evan Gappelberg. Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility. , an innovative private life science company with an extensive portfolio of issued patents in next-generation nucleic acid. CA, an investment chat community for Canada's small cap markets. The Board of Directors of Biocept Inc. Brazil Patent Granted for Biocept's Target Selector™ Oncogene Mutation Enrichment and Detection Platform - Biocept, Inc. Reeves brings more than 25 years of marketing and management experience and comes to Illumina from Cardinal Health, where she was senior VP of enterprise marketing and general manager of the medical. Share this article. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, and Aegea Biotechnologies, Inc. (BIOC) como el resumen financiero, información sobre la industria y el sector, la cantidad de empleados, la gestión corporativa, los miembros ejecutivos clave y sus compensaciones. He is the President and Chief Executive Officer of Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Deprecated: implode(): Passing glue string after array is deprecated. Run by investors for investors Proactive Investors is a Leading source of in-depth comment, analysis, financial news, press releases and share price data on small to large capitalised companies on the Australian Stock Exchange, Toronto Stock Exchange. “The healthcare community recognizes the importance of determining molecular biomarker status in making treatment decisions for cancer patients,” said Michael Nall, President and CEO of Biocept. Implicit in this philosophy is the importance of sound corporate governance. (Nasdaq: BIOC), a Biocept's President and CEO. “Immunotherapy is among today's most promising approaches to improving the outcomes of patients with cancer and shows even greater potential in the future as drugs currently in development come to market,” said Michael Nall, Biocept's president and CEO. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces the appointment of Michael C. Chandler is a member of Biocept's science and technology committee. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Biocept CEO Michael Nall in a statement. At the time of writing, our data says that Biocept, Inc. This analysis aims first to contrast CEO compensation Simply Wall St. "This agreement provides Biocept with new incremental revenue for R&D development services and, if successfully developed. 04 per share. —San Diego’s Biocept,. "Our highly sensitive and highly specific assays that can profile cancer-associated biomarkers from a blood sample demonstrate a clear advancement in the move to precision medicine," said Biocept's president and CEO, Michael Nall, in a statement. Biocept (BIOC +4. Corporate governance Biocept, Inc. Address: 5810 Nancy Ridge Drive, Suite 150, San Diego, CA, USA, 92121: Telephone: +1 858 320-8200: Website: https://www. The following slide deck was published by Biocept, Inc. 27, 2020 /PRNewswire/ -- Biocept, Inc. | 3,574 Follower auf LinkedIn | When treating cancer, it's no longer an either/or world. (BIOC) CEO Michael Nall on Q4 2019 Results - Earnings Call Transcript. Biocept - Proactive's One2One Virtual Investor Forum. Biocept will begin accepting physician-ordered testing to support our clients and public health efforts by expanding our offerings to include COVID-19 testing,” said Biocept CEO Mike Nall. Biocept (NASDAQ:BIOC) CEO Mike Nall will be presenting at Proactive's One2One Virtual Event on Tuesday, August 25th at 1pm EST. NEW YORK -- Biocept - Get Report shares are rallying 6. 's ISS Governance QualityScore as of N/A is N/A. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. Biocept (BIOC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). President & CEO Ligand Dx (LW Ligand, Inc. (NASDAQ:BIOC) Q2 2019 Earnings Conference Call. President and CEO of Biocept. Wainwright Global. Find the latest Biocept, Inc. 0% compared to the same quarter a year ago. 3% to 58 cents at the time of publication Monday. Shares of Biocept Inc (NASDAQ: biomarker assay or a larger NGS-based liquid biopsy test panel for use when more comprehensive testing is desired," CEO Michael Nall said in a statement. Then we'll look. About Biocept Biocept, Inc. (NASDAQ:BIOC) in 2013. Feb 04, 2020, 08:05 ET. ’s ISS Governance QualityScore as of N/A is N/A. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Michael Nall, Biocept's President and CEO. Togo Group CEO on road trip trends. as Chief Medical Officer and Medical Director. 27, 2020 /PRNewswire/ -- Biocept, Inc. 16M fixed-price-incentive-firm-target contract for the production and delivery of eight UH-1Y and four AH-1Z helicopters for the government of the Czech Republic. SAN DIEGO, Aug. How the unprecedented race for a vaccine is unfolding By Eliza Mackintosh,Gianluca Mezzofiore and Katie Polglase, CNN Published August 14,. Illumina has announced that Kathryne Reeves will join the firm as chief marketing officer on Sept. we just heared that bioc has until Dec 7 2020 to satisfy the Nasdaq $1 minimum bid requirement. Biocept (BIOC +4. The group operates and supports more than 50 facilities in multiple states, with most located. Corporate Governance Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California. 85% Biocept, Inc. CA #bioc Biocept, Inc. 13 in a total of its share price and finished its trading at 0. share price prognosis for 2020, 2021, 2022, 2023, 2024. Dugan has more than 25 years of industry experience, most recently as president and CEO of professional advisory group practice MCDXI Medical Diagnostics. In fact, the company said that it plans to begin accepting oders from physicians and processing these orders starting on April 15, 2020. The Zacks rating relies solely on a company's changing earnings picture. (Nasdaq: BIOC), a leading commercial provider. The Biotechnology Innovation Organization is the world's largest biotech trade association. Support: 888-992-3836 Biocept to Release First Quarter 2020 Financial Results and Host Investor Conference. 4, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients. Biocept - Proactive's One2One Virtual Investor Forum. Biocept, Inc. 13, 2020 /PRNewswire via COMTEX/ -- SAN DIEGO, Aug. The analyst consensus points to a rating of ‘Buy’. Chandler is a member of Biocept's science and technology committee. 38 per share in the second quarter of 2019. Togo Group CEO on road trip trends. , an innovative private life science company with an extensive portfolio of issued patents in next-generation nucleic. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Michael Nall, Biocept's President and CEO. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall presents to investors at Proactive's One2One Virtual Investor Forum. was founded in 1997 and is headquartered in San Diego, California. Tax Planning; Personal Finance; Save for College; Save for Retirement; Invest in Retirement. This is the Biocept company profile. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. PD-L1 is a molecule often expressed on. Encuentra el debate de accionesBiocept, Inc. 5%) is up, albeit on below-average volume, in reaction to its announcement that it has processed more than 20K COVID-19 specimens in its molecular lab, most reported within 48. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. Biocept will begin accepting physician-ordered testing to support our clients and public health efforts by expanding our offerings to include COVID-19 testing,” said Biocept CEO Mike Nall. Get the latest Biocept, Inc. Biocept, Inc. The Company uses its proprietary. 6, 2020 /PRNewswire/ -- Biocept, Inc. In a statement, Biocept President and CEO Michael Nall said that the agreement marks the first step in Biocept's goal to transform itself from an exclusive CLIA lab business to a technology and products company. The following slide deck was published by Biocept, Inc. 85% Biocept, Inc. Thursday, October 01, 2015 $BIOC Biocept CEO Discusses Liquid Biopsy Diagnostic Test - StockNewsNow. Learn about BIO, register for events and explore member services. , Suite 150 San Diego, CA 92121 Customer Service: 888. 7729 Company Operator: 858. is a commercial stage oncology diagnostics company. Biocept (NASDAQ:BIOC) CEO Mike Nall will be presenting at Proactive's One2One Virtual Event on Tuesday, August 25th at 1pm EST. Biocept CEO and key executive team. , a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve outcomes, announces it has entered into an agreement with a healthcare group to provide COVID-19 testing to skilled nursing facilities. Here’s what’s happening: Stop […]. It comes after the group's one-for-ten (ten shares combined and converted into one) reverse stock split which became effective at 5pm EST on September 4 this year. SAN DIEGO, Feb. , a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. Get Biocept Inc (B002-FF:Frankfurt Stock Exchange) real-time stock quotes, news and financial information from CNBC. CA, an investment chat community for Canada's small cap markets. SAN DIEGO, May 29, 2020 /PRNewswire/ — Biocept, Inc. Mike Nall became the CEO of Biocept, Inc. Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. 05 per share on revenue of $0. To accommodate the robust demand for this testing, we have increased staffing. 27, 2020 /PRNewswire/ -- Biocept, Inc. Business: Diagnostic Hired: Michael Nall as president and CEO, formerly general manager of North American sales and marketing at General Electric's Clarient Diagnostic Services Inc. Nall will present a corporate overview at the 22 nd Annual BIO CEO & Investor Conference on Monday. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive the California-based company's Target Selector liquid biopsy tests are now available to detect cancer biomarkers in cerebrospinal fluid. The declines come after the company issued its financial results, leaving investors with mixed feelings. Growing? Biocept, Inc. Entering into the global market with a scaled offering for liquid biopsy is the first step toward growing from an exclusive CLIA lab business to a technology and products company. SAN DIEGO, May 29, 2020 /PRNewswire/ — Biocept, Inc. ’s ISS Governance QualityScore as of N/A is N/A. Real time Biocept (BIOC) stock price quote, stock graph, news & analysis. Coutts , who was named as Biocept's CEO in 2008, told me he had just lost a daughter to cancer, and he convinced the board that cancer diagnostics was the best use of Biocept's technology. (NASDAQ:BIOC) in 2013. Nail, President and CEO at Biocept, had the following to offer: “ We are executing on a stated objective for 2016 of increasing the utilization of our tests in clinical. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Biocept (BIOC) Recent Earnings. 04 per share. Nall is a healthcare executive with over 25 years of experience. 27, 2020 /PRNewswire via COMTEX/ -- SAN DIEGO, Aug. , a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports. , local time, at the offices of Biocept, Inc. 3%) Volume:. com - 16 - Shares of Biocept Inc. The company’s cancer assays provide an information to oncologists and other physicians that enable them to select personalized treatment for their patients based on detailed data on the characteristics of tumors. Nall’s extensive commercialization, sales and marketing. 27, 2020 /PRNewswire/ -- Biocept, Inc. Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020. , an innovative private life science company with an extensive portfolio of issued patents in next-generation nucleic. Biocept thermo fisher covid. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Michael Nall, Biocept's President and CEO. Michael Nall, CEO & President, Director at Biocept (BIOC), is currently unranked, see this insider's latest transactions. “The healthcare community recognizes the importance of determining molecular biomarker status in making treatment decisions for cancer patients,” said Michael Nall, President and CEO of Biocept. NasdaqCM:BIOC CEO Compensation, July 11th 2019 Is Biocept, Inc. Below is a representative list of partnering companies for the 2020 CEO & Investor Conference: 20/20 GeneSystems 3E Bioventures 3i Fund A C Binder Corp A2A Pharmaceuticals Ab Studio AbbVie Abingworth Management Accelmed Partners Aceras Partners …. 2020 is expected to be a huge year for penny stocks. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Find the latest Biocept, Inc. 13 mins Biocept Announces One-for-Ten Reverse Stock Split Business Insider 22 mins Stocks Fall in Another Volatile Session – Morningstar. Biocept, Inc. stock is -39. In a statement, Biocept President and CEO Michael Nall said that the agreement marks the first step in Biocept's goal to transform itself from an exclusive CLIA lab business to a technology and products company. He has served as President and CEO of Biocept for the past 4 years, leading the company from R and D stage to a fully commercialized entity. A corporate filing is called a foreign filing when an existing corporate entity files in a. "This agreement effectively expands our managed care network of covered lives at a time when the healthcare community increasingly recognizes the importance of our liquid biopsy tests in helping physicians to determine the optimal treatment for their patients with cancer," said Michael Nall, Biocept's President and CEO. Biocept president and CEO Michael Nall said: “We are excited to announce this milestone, that our proprietary specimen collection tubes and shipping kits are now commercially available in Europe, consistent with our quest to brand Biocept globally as a leading technology provider in the liquid biopsy segment.